Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (Prasugrel, LY640315), a novel P2Y12 receptor inhibitor
Michihiro Hasegawa, Fumitoshi Asai(Azabu University), Atsuhiro Sugidachi(Daiichi Sankyo (United Kingdom)), Taketoshi Ogawa(Biomedical Research Laboratories (United States)), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Takashi Isobe(Hamamatsu Photonics (United Kingdom))
Cited by 63
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617